CONSTIPATION (REPORT 2: TREATMENT) (literature review)
https://doi.org/10.51523/2708-6011.2014-11-2-4
Abstract
The article discusses the problem of choosing a method of constipation treatment from the point of view of evidence-based treatment taking into account individual characteristics of a patient. It presents data on the most effective and safe drugs for the treatment of constipation as well as indications for the application of biological feedback method and surgery.
About the Authors
E. N. Platoshkin
Gomel State Medical University
Belarus
Belarus
S. A. Shut
Gomel State Medical University
Belarus
Belarus
References
1. Буторова, Л. И. Запор: диагностика и основные принципы назначения слабительных средств / Л. И. Буторова // Клин. перспективы гастроэнтерологии, гепатологии. - 2003. - № 4. - С. 19-25.
2. Tack, J. Treatment of chronic constipation: current pharmacologic approaches and future directions / J. Tack, S. Müller-Lissner // Clin. Gastroenterol. Hepatol. - 2009. - Vol. 7. - P. 502-508.
3. World Gastroenterology Organisation Global Guidelines. Constipation: a global perspective. November 2010. [Electronic resourse] Mode of access: http://www.worldgastroenterology.org/constipation.html. - Date of accessed 20 January 2013.
4. Шептуллин, А. А. Новые возможности лекарственной терапии хронических запоров [Electronic resourse] / ed. А. А. Шептуллин. - Mode of access: http://www. internist.ru/articles/ gastroenterology/ gastroenterology_414.html. - Date of accessed: 05 February 2014.
5. Sanger, G. J. Constipation, IBS and the 5-HT4 receptor: what role for prucalopride? / G. J. Sanger, E. M. M. Quigley // Clin Med Insights: Gastroenterology. - 2010. - № 3. - Р. 21-33.
6. Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder / E. P. Bouras [et al.] // Gastroenterology. - 2001. - № 120. - P. 354-360.
7. Effects of prucalopride on colonic transit, anorectal function and bowel habits in patients with chronic constipation / C. E. Sloots [et al.] // Aliment Pharmacol Ther. - 2002. - Vol. 16. - P. 759-767.
8. Effect of prucalopride, a new enterokinetic agent, on gastrointestinal transit and anorectal function in healthy volunteers / A. C. Poen [et al.] // Aliment Pharmacol Ther. - 1999. - Vol. 13. - P. 1493-1497.
9. Effect of a novel prokinetic drug, R093877, on gastrointestinal transit in healthy volunteers / A. V. Emmanuel [et al.] // Gut. - 1998. - Vol. 42. - P. 511-516.
10. Safety assessment of prucalopride in elderly patients with constipation: a double-blind, placebo-controlled study / M. Camilleri, [et al.] // Neurogastroenterol Motil. - 2009. - Vol. 21. - P. 1256-1317.
11. Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation / J. F. Johanson [et al.] // Aliment Pharmacol Ther. - 2008a. - Vol. 27. - P. 685-696.
12. Метод биологической обратной связи (biofeedback) [Electronic resourse] / Mode of access: www.airmed.com.ua. Date of accessed 11 February 2014.
13. Рекомендации по диагностике и лечению хронического запора: Методическое пособие / В. Т. Ивашкин [и др.]. - М.: ООО «НПЦ Мединформ», 2014. - 6 с.
14. Diagnosis and treatment of chronic constipation - a European perspective / J. Tack [et al.] // Neurogastroenterol Motil. - 2011. - Vol. 23. - P. 697-710.
15. Treatment of GI dysmotility in scleroderma with the new enterokinetic agent prucalopride / G. E. Boeckxstaens [et al.] // Am J Gastroenterol. - 2002. - Vol. 97. - P. 194-197.
16. Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans / E. P. Bouras [et al.] // Gut. - 1999. - Vol. 44. - P. 682-686.
17. Cardiovascular safety of prucalopride in healthy subjects: results from two randomized, double-blind, placebo-controlled, cross-over trials [abstract] / M. Boyce [et al.] // Gastroenterology. - 2009. - Vol. 136. (Suppl. 1). - T. 1265.
18. An evidence-based systematic review of the management of irritable bowel syndrome / L. J. Brandt [et al.] // Am J Gastroenterol. - 2009. - Vol. 104. - P. 1-35.
19. Evidence-based position statement on the management of chronic constipation in North America / L. J. Brandt [et al.] // Am J Gastroenterol. - 2005. - Vol. 100 (Suppl. 1). - P. 5-21.
20. A placebo-controlled trial of prucalopride for severe chronic constipation / M. Camilleri [et al.] // N Engl J Med. - 2008b. - Vol. 358. - P. 2344-2354.
21. Clinical trial: the efficacy of open-label prucalopride treatment in patients with chronic constipation - follow-up of patients from the pivotal studies / M. Camilleri [et al.] // Aliment Pharmacol Ther. - 2010. - Vol. 32. - P. 1113-1123.
22. Functional characterization of contractions to tegaserod in human isolated proximal and distal coronary arteries / K. Y. Chan [et al.] // Eur J Pharmacol. - 2009. - Vol. 619. - P. 61-67.
23. Prucalopride is effective in patients with severe chronic constipation in whom laxatives fail to provide adequate relief. Results of a double-blind, placebo-controlled clinical trial / G. Coremans [et al.] // Digestion. - 2003. - Vol. 67. - P. 82-89.
24. The effects of the specific 5HT(4) receptor agonist, prucalopride, on colonic motility in healthy volunteers / A. M. De Schryver [et al.] // Aliment Pharmacol Ther 2002. - Vol. 16. - P. 603-612.
25. A randomized, multicenter comparison of polyethylene glycol laxative and tegaserod in treatment of patients with chronic constipation / J. A. Di Palma [et al.] // Am J Gastroenterol. - 2007. - Vol. 102. - P. 1964-1971.
26. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome - results of two randomized, placebo-controlled studies / D. A. Drossman [et al.] // Aliment Pharmacol. Ther. - 2009. - Vol. 29. - P. 329-341.
27. Psychometric performance and clinical meaningfulness of the Patient Assessment of Constipation-Quality of Life questionnaire in prucalopride (RESOLOR) trials for chronic constipation / D. Dubois [et al.] // Neurogastroenterol Motil. - 2010. - Vol. 22. - P. 54-63.
28. Pharmacological management of constipation / A. V. Emmanuel [et al.] // Neurogastroenterol. Motil. - 2009. - Vol. 21, (Suppl. 2). - P. 41-54.
29. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locallyacting type-2 chloride channel activator, in patients with chronic constipation / J. F. Johanson[et al.] // Am J Gastroenterol. - 2008b. - Vol. 103. - P. 170-177.
30. Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation / J. M. Johnston [et al.] // Gastroenterology. - 2010. - Vol. 139. - P. 1877-1886.
31. Efficacy and tolerability of prucalopride in patients with constipation due to spinal cord injury / K. Krogh [et al.] // Scand J Gastroenterol. - 2002. - Vol. 37. - P. 431-436.
32. Efficacy of linaclotide for patients with chronic constipation / A. J. Lembo [et al.] // Gastroenterology. - 2010. - Vol. 138. - P. 886-895.
33. A double-blind, placebo-controlled study of prucalopride in elderly patients with chronic constipation / S. Müller-Lissner [et al.] // Neurogastroenterol Motil. - 2010. - Vol. 22. - P. 991-998.
34. Gastrointestinal prokinetic drugs have different affinity for the human cardiac human ether-a-gogo K(+) channel / F. Potet [et al.] // J Pharmacol Exp Ther. - 2001. - Vol. 299. - P. 1007-1012.
35. Quigley, E. M. M. Cisapride. What can we learn from the rise and fall of a prokinetic? / E. M. M. Quigley // J Dig Dis. - 2011. - Vol. 12. - P. 147-156.
36. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation - a 12-week, randomized, double-blind, placebo-controlled study / E. M. Quigley [et al.] // Aliment Pharmacol Ther. - 2009. - Vol. 29. - P. 315-328.
37. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives / J. Tack [et al.] // Gut. - 2009. - Vol. 58. - P. 357-365.
Review
For citations:
Platoshkin E.N., Shut S.A. CONSTIPATION (REPORT 2: TREATMENT) (literature review). Health and Ecology Issues. 2014;(2):21-25. (In Russ.) https://doi.org/10.51523/2708-6011.2014-11-2-4
Views: 265
Email this article 